Dexcom Executive Chairman Kevin Sayer Returns From Leave
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dexcom ( (DXCM) ) has provided an update.
Dexcom announced that long-time leader Kevin R. Sayer, who had informed the board in July 2025 of his plan to retire as chief executive officer effective January 1, 2026, was appointed executive chairman of the board as of that same date to provide ongoing leadership and strategic guidance. The move marks a transition from his CEO role while retaining his influence over the company’s direction and continuity at the board level.
After taking a temporary leave of absence effective September 14, 2025, Sayer notified Dexcom on February 27, 2026, that he would return from leave on March 2, 2026, at which point he resumed his duties as executive chairman and Mark Foletta returned to his role as lead independent director. On the same date, Sayer entered into a letter agreement setting an annual base salary of $610,000 and granting him restricted stock units valued at $2.35 million that vest on March 8, 2027, while he remains eligible for standard executive benefits but no longer participates in the company’s severance and change-in-control plan, clarifying his long‑term incentives and governance role for investors and other stakeholders.
The most recent analyst rating on (DXCM) stock is a Buy with a $83.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.
Spark’s Take on DXCM Stock
According to Spark, TipRanks’ AI Analyst, DXCM is a Outperform.
DXCM scores well on financial performance (strong growth, profitability, and improved leverage) and is supported by upbeat 2026 guidance emphasizing margin expansion and product catalysts. The overall score is tempered by premium valuation (P/E ~35) and a mixed longer-term technical backdrop with the 200-day average slightly above the current price.
To see Spark’s full report on DXCM stock, click here.
More about Dexcom
Dexcom, Inc. is a medical technology company specializing in continuous glucose monitoring systems for people with diabetes. Its primary products help patients and healthcare providers track glucose levels in real time, positioning the company as a key player in the diabetes management and digital health markets.
Average Trading Volume: 5,264,397
Technical Sentiment Signal: Sell
Current Market Cap: $28.26B
Learn more about DXCM stock on TipRanks’ Stock Analysis page.
